乳腺腫瘤標(biāo)志（CA 15-3）檢測(cè)試劑盒（酶聯(lián)免疫法）產(chǎn)品說(shuō)明:

【產(chǎn)品名稱(chēng)】

通用名稱(chēng)：乳腺腫瘤標(biāo)志（CA 15-3）檢測(cè)試劑盒（酶聯(lián)免疫法）

英文名稱(chēng)：CA 15-3 ELISA

【預(yù)期用途】

CA15-3 ELISA試劑盒用于定量測(cè)定人血清或血漿中的癌抗原CA15-3濃度。。僅供科研使用，不用于體外診斷。

【背景知識(shí)】

乳腺癌是當(dāng)今發(fā)達(dá)國(guó)家婦女最常見(jiàn)的威脅生命的惡性病變，每年約有180000例新診斷病例。這些新診斷的患者中大約有一半是淋巴結(jié)陰性，然而這些病例中有30%進(jìn)展為轉(zhuǎn)移性疾病。

有許多腫瘤標(biāo)志物可以幫助臨床醫(yī)生識(shí)別和診斷哪些乳腺癌患者會(huì)有更具侵襲性的疾病。這些標(biāo)記物包括雌激素和孕激素受體、DNA倍體和S期百分比、表皮生長(zhǎng)因子受體、HER-2/新癌基因、p53腫瘤抑制基因、組織蛋白酶D、增殖標(biāo)記物和CA15-3。CA15-3在監(jiān)測(cè)患者術(shù)后復(fù)發(fā)方面最為有效，尤其是在轉(zhuǎn)移性疾病病例中。96%的局部和全身復(fù)發(fā)患者的CA15-3升高，這可用于比放射學(xué)和臨床標(biāo)準(zhǔn)更早地預(yù)測(cè)復(fù)發(fā)。血清CA15-3升高25%與癌的進(jìn)展相關(guān)。血清CA15-3降低50%與治療反應(yīng)有關(guān)。CA15-3在早期檢測(cè)乳腺癌復(fù)發(fā)方面比CEA更敏感。聯(lián)合CA125、CA15-3在卵巢癌復(fù)發(fā)的早期檢測(cè)中是有用的。結(jié)腸、肺和肝腫瘤中的CA15-3水平也升高。

【包裝規(guī)格】

96T/盒

樣本量：25μl

保存溫度：2-8℃

參考文獻(xiàn)：

1. Aziz DC, Peter JB. DNA ploidy and cell-cycle analysis. Tools for assessment of cancer prognosis. J Clin Pathol 1991;5:422-38.

2. Clark GM, Dressler LG, Owens MA, Dounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-33.

3. Elledge RM, McGuire WL. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Annu Rev Med 1993;44:201-10.

4. Foekens JA, Rio C, Seguin P, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein. Cancer Res 1990; 50-3832-7.

5. Isola J, Visakorp T, Holli K, Kallionieml D. Association of p53 expression with other prognostic factors and long term survival in node-negative breast cancer. J Cell Biochem 1992;(Suppl 16D):101.

6. Kute TE, Shao ZM, Snugg NK, Long RT, Russell GB, Case LD. Cathepsin D as a prognostic indicator for nodenegative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 1992;52-198-203.

7. McGuire WL, Tandon AK, Allred D, Chamnes GC, Clark GM. How to use prognostic factors in axillary node negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-7.

8. Nicholson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFr): results of a 6 year follow up study in operable breast cancer with emphasis on the node-negative subgroup. Br J Cancer 1991;63:146-50.

9. Somerville JE, Clarke LA, Biggart JD. C-erb B-2 overexpression and histological type of in-situ and invasive breast carcinoma. J Clin Pathol 1992;45-16-20.